T541通过恢复脑微血管完整性减轻4.5小时tPA溶栓后的血管性水肿和出血
研究在颈动脉血栓小鼠模型中于4.5小时给予tPA伴或不伴T541干预,观察溶栓、脑血流及24小时脑水肿出血与微血管连接蛋白变化,并用体外缺氧复氧模型评估T541对紧密连接的影响。结果显示tPA在4.5小时给药减少血栓面积但降低生存率且无脑血流获益,T541剂量依赖性减轻tPA相关血管性水肿、出血、连接蛋白下降和能量代谢障碍。
要点
- 4.5小时tPA溶栓减少血栓面积但降低生存率,对脑血流无获益。
- tPA后24小时缺血半球出现显著血管性水肿和出血,连接蛋白表达下降。
- T541剂量依赖性减轻tPA后血管性水肿、出血及能量代谢障碍。
核心结论
- 结果提示T541可能作为减轻延迟tPA相关血管性水肿和出血并延长tPA治疗时间窗的潜在治疗手段。
- T541上调能量代谢和保护血脑屏障的潜力可能归因于其所观察到的效应。
研究设计与样本
- 雄性C57BL/6 N小鼠经10% FeCl3刺激建立颈动脉血栓模型,在4.5小时给予10 mg/kg tPA伴或不伴20 mg/kg T541干预。
- 动态观察溶栓和脑血流至药物治疗后24小时,并评估神经功能缺损评分、脑水肿和出血、脑微血管连接和基底膜蛋白及皮质能量代谢。
- 采用人脑微血管内皮细胞体外缺氧/复氧模型评估tPA存在下T541对紧密连接和F-actin的影响。
主要发现
- 颈动脉血栓后4.5小时给予tPA导致血栓面积减少和生存率降低,而对脑血流无获益。
- tPA给药后24小时缺血半球出现显著血管性水肿和出血,连接蛋白claudin-5、zonula occludens-1、occludin、junctional adhesion molecule-1和vascular endothelial cadherin及collagen IV和laminin表达下降。
- 同时ADP/ATP、AMP/ATP和ATP5D表达及线粒体复合物I、II和IV活性下降,而malondialdehyde和8-Oxo-2'-deoxyguanosine升高且F-actin排列紊乱。
- 加入T541剂量依赖性减轻tPA治疗后的上述所有损伤。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- tPA (tissue-type plasminogen activator) is the only recommended intravenous thrombolytic agent for ischemic stroke. However, its application is limited because of increased risk of hemorrhagic transformation beyond the time window. T541 is a Chinese compound medicine with potential to attenuate ischemia and reperfusion injury. This study was to explore whether T541-benefited subjects underwent tPA thrombolysis extending the time window. Methods- Male C57BL/6 N mice were subjected to carotid artery thrombosis by stimulation with 10% FeCl3 followed by 10 mg/kg tPA with/without 20 mg/kg T541 intervention at 4.5 hours. Thrombolysis and cerebral blood flow were observed dynamically until 24 hours after drug treatment. Neurological deficit scores, brain edema and hemorrhage, cerebral microvascular junctions and basement membrane proteins, and energy metabolism in cortex were assessed then. An in vitro hypoxia/reoxygenation model using human cerebral microvascular endothelial cells was used to evaluate effect of T541 on tight junctions and F-actin in the presence of tPA. Results- tPA administered at 4.5 hours after carotid thrombosis resulted in a decrease in thrombus area and survival rate, whereas no benefit on cerebral blood flow. Study at 24 hours after tPA administration revealed a significant angioedema and hemorrhage in the ischemia hemisphere, a decreased expression of junction proteins claudin-5, zonula occludens-1, occludin, junctional adhesion molecule-1 and vascular endothelial cadherin, and collagen IV and laminin. Meanwhile, ADP/ATP, AMP/ATP, and ATP5D (ATP synthase subunit) expression and activities of mitochondria complex I, II, and IV declined, whereas malondialdehyde and 8-Oxo-2'-deoxyguanosine increased and F-actin arrangement disordered. All the insults after tPA treatment were attenuated by addition of T541 dose dependently. Conclusions- The results suggest T541 as a potential remedy to attenuate delayed tPA-related angioedema and hemorrhage and extend time window for tPA treatment. The potential of T541 to upregulate energy metabolism and protect blood-brain barrier is likely attributable to its effects observed.
引用
- Chen QF, Liu YY, Pan CS, et al. Angioedema and Hemorrhage After 4.5-Hour tPA (Tissue-Type Plasminogen Activator) Thrombolysis Ameliorated by T541 via Restoring Brain Microvascular Integrity. Stroke. 2018. PMID: 30354988. doi:10.1161/STROKEAHA.118.021754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。